dr. cost on pembrolizumab plus axitinib in patients with rcc
Published 7 years ago • 378 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
1:34
dr. rini on pembrolizumab plus axitinib in rcc
-
1:40
dr. powles on fda approval of pembrolizumab plus axitinib in advanced rcc
-
1:17
dr. vaishampayan on axitinib plus pembrolizumab in advanced rcc
-
1:04
dr. rini discusses pembrolizumab plus axitinib in mrcc
-
1:03
dr. rini on managing the toxicity of pembrolizumab plus axitinib in mrcc
-
1:19
dr. rini on the efficacy of axitinib and pembrolizumab in rcc
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
2:17
dr. chowdhury on pembrolizumab plus pazopanib in rcc
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
1:14
dr. wilky on pembrolizumab plus axitinib in sarcoma
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
3:03
adjuvant pembrolizumab improves rcc disease-free survival | toni choueiri
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
4:40
pembrolizumab plus axitinib in the second-line and beyond for mrcc
-
2:23
overview of a phase iii trial of pembrolizumab plus axitinib in rcc